Genocea Biosciences high volatility trend continues
 | By Raphi Shpitalnik | Macroaxis Story |
Genocea Biosciences is currently generating 0.8018% in daily expected returns and assumes 5.8187% risk (volatility on return distribution) over the 60 days horizon. As many old-fashioned traders are trying to avoid healthcare space, it makes sense to go over Genocea Biosciences a little further and try to understand its current volatility patterns. We will analyze if the expected returns on Genocea Biosciences will justify its current volatility. Genocea Biosciences high volatility, while potentially profitable, can lead to more considerable losses for your portfolios.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
This firm currently holds 25.54 M in liabilities with Debt to Equity (D/E) ratio of 1.96, which is about average as compared to similar companies. The company has a current ratio of 1.94, which is within standard range for the sector. On a scale of 0 to 100, Genocea Biosciences holds a performance score of 9. The company retains a Market Volatility (i.e. Beta) of 0.6395, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Genocea's beta means in this case. As returns on the market increase, Genocea Biosciences returns are expected to increase less than the market. However, during the bear market, the loss on holding Genocea Biosciences will be expected to be smaller as well. Although it is vital to follow Genocea Biosciences current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for Genocea Biosciences, which you can use to evaluate the performance of the firm. Please utilizes Genocea Biosciences maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to make a quick decision on whether Genocea Biosciences current trending patterns will revert. Volatility is a rate at which the price of Genocea Biosciences or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Genocea Biosciences may increase or decrease. In other words, similar to Genocea's beta indicator, it measures the risk of Genocea Biosciences and helps estimate the fluctuations that may happen in a short period of time. So if prices of Genocea Biosciences fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.
Watch out for price decline
Please consider monitoring Genocea Biosciences on a daily basis if you are holding a position in it. Genocea Biosciences is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Genocea Biosciences stock to be traded above the $1 level to remain listed. If Genocea Biosciences stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Genocea Biosciences's Liquidity
Genocea Biosciences financial leverage refers to using borrowed capital as a funding source to finance Genocea Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Genocea Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Genocea Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Genocea Biosciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Genocea Biosciences's total debt and its cash.
Is Genocea Biosciences valued fairly by the market?
The latest price spikes of Genocea Biosciences may raise some interest from investors. The stock closed today at a share price of 2.69 on very low momentum in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.82. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Genocea Biosciences partners.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Genocea Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.